Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people achieve financial freedom through our website, podcasts and books, newspaper column, radio broadcast and premium investment services

Pharmaceutical companies Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ) are two of the biggest players in the race to vaccinate the world against COVID-19. Pfizer vaccine, made in coordination with BioNTech, was approved by the U with awarded the Emergency Use Authorization (EUA) S. Food and Drug Administration (FDA) on Dec. 11, which gives it an edge over all other coronavirus vaccines in the U.S.

Usually vaccines take years, not months, to develop. Johnson & Johnson’s vaccine, which may hit the market as early as February, may, for practical reasons and because of the strength of manufacturing, be the largest pharmaceutical company in the world with more than 130000 employees may ultimately be the preferred option Let’s find out which coronavirus is the better choice today

Pfizer’s vaccine must be shipped at around minus 70 degrees Celsius and requires special freezers before it is thawed for use It is then given in two doses about three weeks apart It stimulates the recipient’s body to spike Produce proteins that mimic those of the virus Instructions are used that are transmitted via the messenger ribonucleic acid (mRNA) These proteins spur your immune system to produce antibodies that fight SARS-CoV-2, the virus that causes COVID-19

Johnson & Johnson’s vaccine candidate is still in a Phase 3 trial, but could receive its EUA from the FDA as early as February, according to the Department of Health and Human Services. J&J’s vaccine requires only one dose and can be in a typical Refrigerated, which reduces logistical problems.Deoxyribonucleic acid (DNA) is used instead of RNA to induce the recipient to fight SARS-CoV-2 To do this, a weakened version of a cold virus, adenovirus 26, is used to transport genetic material from the spike protein contained in SARS-CoV-2 into the body, which causes the immune system to produce antibodies that defend itself against it

Pfizer obviously has a head start, but only 6% of the people in the USAS, according to USA Today received coronavirus vaccine and only 1% have already received two doses Pfizer announced it had produced more than 70 million doses by the end of December and, along with BioNTech, has committed to producing 2 billion more for the U.S until July

Johnson & Johnson’s vaccine, which has simpler refrigerated storage requirements, better portability and requires only a single dose, could overshadow its competitors, the company announced this week that it is on the right track by the end of June To produce 100 million doses of its vaccine Pfizer vaccine has been shown to be 95% effective in preventing coronavirus infection.In interim results, the New England Journal of Medicine reported only that the effectiveness of Johnson’s vaccine was & Johnson about 90% lay

Johnson & Johnson’s vaccine may have an advantage in that it is almost as effective but much more convenient and easier to distribute

If you’re buying one of these pharmaceutical stocks just because of a coronavirus bump, you’re seeing them wrong, both stocks have great long-term potential

Pfizer stock offers an annual dividend of $ 152 per share, one of the best dividends among the big drug companies, with a current yield of 418%, the cash dividend payout ratio is 80, so there is concern that the dividend may be lowered, since it has increased more than 171% over the past 10 years, meaning that earnings growth has slowed compared to the company’s dividend growth, one reason for the high return is that Pfizer’s sales have declined for two consecutive years and the stock is down more than 3.5% last year, the company’s revenue was $ 121 billion in the third quarter, 4% less than last year. In the first nine months of 2020, the company was $ 359 billion, down 8 % over the same period in 2019

One thing that could be said for Pfizer is that it sells at a higher discount with a value for money (P / E) of around 23 compared to Johnson & Johnson at a higher discount if you are, however looking at forward P / E, which takes into account expected earnings, Johnson & Johnson is cheaper at 11 to Pfizer’s 18 This suggests lower expected sales growth for Johnson & Johnson

Johnson & Johnson is a dividend king who has increased its dividend for 58 straight years. The annual dividend was $ 4,004 per share last year after a 63% increase, giving a current yield of 236% and a safe payout ratio of 5,639 Johnson & Johnson’s shares are up more than 13% over the past year J&J just released its fourth quarter report, which shows the company had a solid quarter with reported sales of $ 22.5 billion, up 83% year over year Annual sales rose for the fifth year in a row despite headwinds from the pandemic – despite net income declining 2.7%, in part due to $ 5 billion net litigation costs primarily involving opioid cases

Of the two stocks, I’d go for the safer choice of Johnson & Johnson We’re still in the early stages of coronavirus vaccine sales and Johnson & Johnson will have little trouble catching up as his vaccine is given current distribution opportunities will be more adaptable and useful J&J is much more diversified, although Pfizer is primarily a pharmaceutical company The pharmaceuticals segment leads the way, but the other two businesses – consumer health and medical devices – are big sales drivers which, while slowed by the pandemic, will likely bounce back once the pandemic wears off Johnson & Johnson’s diversification enabled him to get out of the pandemic, and if the vaccine takes off (as many are expecting) the company could have a record year

Market data from FactSet and Web Financial Group

Johnson and Johnson Share

World News – CA – Better Coronavirus Share: Johnson & Johnson vs. Pfizer | The colorful fool

Source: https://www.fool.com/investing/2021/01/29/better-coronavirus-stock-johnson-johnson-vs-pfizer/